O’Regan Weighs Escalation, De-Escalation Approaches in Early-Stage HER2+ Breast Cancer
In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer
In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer
Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.